In this case study, Pharma IQ gains insight from Oxford BioMedica - a pioneer in the development of gene therapies for 20 years, focused mainly on lentiviral vectors. The ebook evaluates manufacturing trends, preparing for the commercial phases of gene therapies, combating extractables and leachables and scaling up.
Please note: That all fields marked with an asterisk (*) are required.
Unsupported Browser Detected
The browser you are using is not supported that will prevent you from accessing certain features of the website. We want you to have the best possible experience. For this you'll need to use a supported browser and upgrade to the latest version.